Tilray Goes Global With Novartis Marijuana Sales Partnership
- Firms will work together to develop and distribute cannabis
- ‘It lends credibility to the product,’ Tilray CEO says
This article is for subscribers only.
Tilray Inc. has signed a global partnership with a division of Swiss drug giant Novartis AG to develop and distribute its medical marijuana in legal jurisdictions around the world.
The Canadian pot firm said Tuesday it’s reached an agreement with Sandoz AG to boost the availability of medical cannabis products globally, building on an existing alliance with Sandoz Canada Inc. The two companies will work together to commercialize Tilray’s non-smokable medical marijuana offerings, co-brand certain products, develop new products and educate pharmacists and physicians about pot.